Back to search

Article

Sintilimab plus irinotecan, leucovorin and 5-fluorouracil (FOLFIRI) as salvage treatment for patients with advanced gastric cancer: real-world evidence from a single-centre cohort

2026-06-01

Abstract excerpt

<title>Abstract</title> <p>Background China is one of the countries with high incidence of gastric cancer, and 30%-40% of patients are metastatic at first diagnosis. The median progression-free survival of immunotherapy combined with chemotherapy as first-line therapy is about half a year, and the benefits of the later-line treatment was limited. This real-world study investigated the efficacy and safety of immu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3d0cf3f4-b502-557e-b332-76ff307d0df1
DOI
10.21203/rs.3.rs-9277582/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Sintilimab plus irinotecan, leucovorin and 5-fluorouracil (FOLFIRI) as salvage treatment for patients with advanced gastric cancer: real-world evidence from a single-centre cohortDOI 10.21203/rs.3.rs-9277582/v1
Complete Remission of a Patient With HER-2 amplification Gastric Cancer Treated With Sintilimab Combined With TrastuzumabSemantic proximity
Efficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): a multicentre, single-arm, exploratory phase 2 studySemantic proximity
Adebrelimab plus apatinib and SOX (AASOX) as conversion therapy for borderline resectable gastric cancer: a single-arm, single-centre, exploratory phase II studySemantic proximity
Autologous Cytokine-Induced Killer (CIK) Cell Immunotherapy plus Sintilimab and Chemotherapy in Advanced Non‒Small-Cell Lung Cancer: 3-Year Outcomes From the Phase Ib CCICC-002a StudySemantic proximity
Efficacy and safety of different PD-1 inhibitors as first-line treatment for advanced or metastatic squamous non-small cell lung cancer: A retrospective real-world studySemantic proximity
Comparative Analysis of Clinical Outcomes Between Neoadjuvant Chemoimmunotherapy and Neoadjuvant Chemoradiotherapy in Patients with Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Retrospective StudySemantic proximity
Molecular biomarkers of response to sintilimab combined with lenvatinib for locally advanced hepatitis B virus-associated hepatocellular carcinomaSemantic proximity
Targeting Gastric Cancer Stem Cells to Enhance Treatment ResponseSemantic proximity
The CD8⁺T/MDSC ratio: A novel prognostic and predictive biomarker for immunotherapy response in gastric cancerSemantic proximity
Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumabSemantic proximity
Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRASG12C inhibitor-naïve Chinese patients with KRASG12C-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies.Semantic proximity
Efficacy and Safety Analysis of Camrelizumab, Sintilimab, and Tislelizumab in the Treatment of NSCLC in Xuanwei, China: A Retrospective Real-World StudySemantic proximity
Select a neighboring publication to make it the new centre.